Devon Energy Corp (DVN) Stock Price Today
Aura AI Summary
Key Stats
- $47.34BMarket Cap
- 14,411,934Volume
- EnergySector
- $52.1552W High
- $34.4652W Low
- 139 DaysTypical Hold Time
- $57.97BEnterprise Value
- 3.08%Div Yield
- 62% Sell | 38% BuyTrading Activity
Track Devon Energy Corp (DVN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Devon Energy Corp has traded between a low of $34.46 and a high of $52.15, highlighting its annual price range. Buy and sell Devon Energy Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Most Recent News
Home Depot and Lowe's see declining sales amid high mortgage rates and weak housing market.
Home Depot and Lowe's reported declines in comparable transactions in Q3 2026 due to a sluggish housing market and rising mortgage rates now above 7%. This has led to fewer home sales and softer demand for home improvement projects, as consumers dela...

Tesla's Cybercab launch signals robotaxi growth in 2027, urging caution on a SpaceX merger before success.
Tesla has started selling Cybercabs, priced at $29,990 with a $299 monthly subscription, but their current use is limited to specific areas and lacks manual controls. This launch is mainly promotional, highlighting Tesla's focus on becoming a transpo...

FDA approval for Grail's Galleri cancer test expected in early 2027, key for insurer coverage and pricing.
Grail expects FDA approval for its multi-cancer early detection test, Galleri, in Q1 2027, which could lead to Medicare and commercial insurer coverage. Despite a failed primary endpoint in a large NHS trial, Galleri showed promising results for 12 d...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.